{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:54:07Z","timestamp":1687784047174},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12913-016-1503-6","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T10:47:08Z","timestamp":1468234028000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study"],"prefix":"10.1186","volume":"16","author":[{"given":"Shu-Mei","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Ta","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"1503_CR1","unstructured":"World Health Organization (WHO). Fact sheets on Hepatitis C. 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ . Accessed 02 Sept 2015."},{"key":"1503_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02540.x","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011. doi: 10.1111\/j.1478-3231.2011.02540.x .","journal-title":"Liver Int"},{"key":"1503_CR3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.24500","volume":"54","author":"DS Chen","year":"2011","unstructured":"Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology. 2011;54:381\u201392.","journal-title":"Hepatology"},{"key":"1503_CR4","first-page":"277","volume":"24","author":"CL Lin","year":"2008","unstructured":"Lin CL, Kao JH. Epidemiology of hepatocellular carcinoma. J Chinese Oncol Soc. 2008;24:277\u201381.","journal-title":"J Chinese Oncol Soc"},{"key":"1503_CR5","unstructured":"Centers for Disease Control and Prevention. Hepatitis C Information for Health Professionals. 2013. http:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm . Accessed 05 May 2013."},{"key":"1503_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir076","author":"BL Pearlman","year":"2011","unstructured":"Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clin Infect Dis. 2011. doi: 10.1093\/cid\/cir076 .","journal-title":"Clin Infect Dis"},{"key":"1503_CR7","first-page":"383","volume":"23","author":"CJ Liu","year":"2012","unstructured":"Liu CJ, Hsu CS, Kao JH. Advances in the treatment of chronic hepatitis C: From interferon to direct acting anti-virals. J Intern Med Taiwan. 2012;23:383\u201391.","journal-title":"J Intern Med Taiwan"},{"key":"1503_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2015.09.008","author":"X Zhang","year":"2016","unstructured":"Zhang X. Direct anti-HCV agents. Acta Pharm Sin B. 2016. doi: 10.1016\/j.apsb.2015.09.008 .","journal-title":"Acta Pharm Sin B"},{"key":"1503_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.21","author":"MS Sulkowski","year":"2011","unstructured":"Sulkowski MS, Cooper C, Hunyady B, Jia J, Oqurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011. doi: 10.1038\/nrgastro.2011.21 .","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1503_CR10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2648.2007.04305.x","volume":"59","author":"M Hopwood","year":"2007","unstructured":"Hopwood M, Treloar C. Pretreatment preparation and management of interferon-based therapy for hepatitis C virus infection. J Adv Nurs. 2007;59:248\u201354.","journal-title":"J Adv Nurs"},{"key":"1503_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2009.08.002","author":"Y Erim","year":"2010","unstructured":"Erim Y, Tagay S, Beckmann M, Bein S, Cicinnati V, Beckebaum S, et al. Depression and protective factors of mental health in people with hepatitis C: A questionnaire survey. Int J Nurs Stud. 2010. doi: 10.1016\/j.ijnurstu.2009.08.002 .","journal-title":"Int J Nurs Stud"},{"key":"1503_CR12","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i3.183","author":"M Nakamura","year":"2016","unstructured":"Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, et al. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol. 2016. doi: 10.4254\/wjh.v8.i3.183 .","journal-title":"World J Hepatol"},{"key":"1503_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75938","author":"EG Meissner","year":"2014","unstructured":"Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014. doi: 10.1172\/JCI75938 .","journal-title":"J Clin Invest"},{"key":"1503_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13011","author":"V Calvaruso","year":"2016","unstructured":"Calvaruso V, Crax\u00ec A. Why do I treat my patients with mild hepatitis C? Liver Int. 2016. doi: 10.1111\/liv.13011 .","journal-title":"Liver Int"},{"key":"1503_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2011.02.006","author":"S Sockalingam","year":"2011","unstructured":"Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE. A comparison of depression screening instruments in Hepatitis C and the impact of depression on somatic symptoms. Psychosomatics. 2011. doi: 10.1016\/j.psym.2011.02.006 .","journal-title":"Psychosomatics"},{"key":"1503_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/SGA.0b013e3181c1497f","author":"M Kinder","year":"2009","unstructured":"Kinder M. The lived experience of treatment for hepatitis C. Gastroenterol Nurs. 2009. doi: 10.1097\/SGA.0b013e3181c1497f .","journal-title":"Gastroenterol Nurs"},{"key":"1503_CR17","first-page":"183","volume":"6","author":"LL Huang","year":"2010","unstructured":"Huang LL, Sung HY, Liu LF, Chang TS. Distress, depression and quality of life in patients with chronic hepatitis C treated with interferon and ribavirin. J Nurs Healthcare Res. 2010;6:183\u201390.","journal-title":"J Nurs Healthcare Res"},{"key":"1503_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/SGA.0b013e318281634e","author":"R Redulla","year":"2013","unstructured":"Redulla R, Dudley-Brown S. Adherence and completion in hepatitis C management: a systematic review. Gastroenterol Nurs. 2013. doi: 10.1097\/SGA.0b013e318281634e .","journal-title":"Gastroenterol Nurs"},{"key":"1503_CR19","doi-asserted-by":"publisher","unstructured":"Treloar C, Hopwood M. \u201cLook, I\u2019m fit, I\u2019m positive and I\u2019ll be all right, thank you very much\u201d: coping with hepatitis C treatment and unrealistic optimism. Psychol Health Med. 2008; doi: 10.1080\/13548500701477532 .","DOI":"10.1080\/13548500701477532"},{"key":"1503_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00001610-200607000-00008","volume":"29","author":"K Sheppard","year":"2006","unstructured":"Sheppard K, Hubbert A. The patient experience of treatment for hepatitis C. Gastroenterol Nurs. 2006;29:309\u201315.","journal-title":"Gastroenterol Nurs"},{"key":"1503_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2702.2009.02806.x","author":"M Sgorbini","year":"2009","unstructured":"Sgorbini M, O\u2019Brien L, Jackson D. Living with hepatitis C and treatment: the personal experiences of patients. J Clin Nurs. 2009. doi: 10.1111\/j.1365-2702.2009.02806.x .","journal-title":"J Clin Nurs"},{"key":"1503_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1043659613481674","author":"NS Jiwani","year":"2013","unstructured":"Jiwani NS, Gul RB, Ali A, Salih M, Hanzala M. Experiences and perceptions of patients living with hepatitis C in Karachi, Pakistan. J Transcult Nurs. 2013. doi: 10.1177\/1043659613481674 .","journal-title":"J Transcult Nurs"},{"key":"1503_CR23","doi-asserted-by":"publisher","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005; doi.org\/ 10.1177\/1049732305276687 .","DOI":"10.1177\/1049732305276687"},{"key":"1503_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2007.04569.x","author":"S Elo","year":"2008","unstructured":"Elo S, Kyng\u00e4s H. The qualitative content analysis process. J Adv Nurs. 2008. doi: 10.1111\/j.1365-2648.2007.04569.x .","journal-title":"J Adv Nurs"},{"key":"1503_CR25","volume-title":"Qualitative Evaluation and Research Methods","author":"MQ Patton","year":"1990","unstructured":"Patton MQ. Qualitative Evaluation and Research Methods. Newbury Park: Sage; 1990."},{"key":"1503_CR26","volume-title":"Naturalistic Inquiry","author":"YS Lincoln","year":"1985","unstructured":"Lincoln YS, Guba EG. Naturalistic Inquiry. Thousand Oaks: Sage; 1985."},{"key":"1503_CR27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5993\/AJHB.33.4.4","volume":"33","author":"EP Stoller","year":"2009","unstructured":"Stoller EP, Webster NJ, Blixen CE, McCormick RA, Perzynski AT, Kanuch SW, et al. Lay management of chronic disease: A qualitative study of living with Hepatitis C infection. Am J Health Behav. 2009;33:376\u201390.","journal-title":"Am J Health Behav"},{"key":"1503_CR28","unstructured":"Centers for Disease Control and Prevention. Viral Hepatitis- Hepatitis C Information. 2015. http:\/\/www.cdc.gov\/hepatitis\/hcv\/ . Accessed 05 March 2016."},{"key":"1503_CR29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i4.1421","author":"R Gonz\u00e1lez-Grande","year":"2016","unstructured":"Gonz\u00e1lez-Grande R, Jim\u00e9nez-P\u00e9rez M, Gonz\u00e1lez Arjona C, Mostazo TJ. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016. doi: 10.3748\/wjg.v22.i4.1421 .","journal-title":"World J Gastroenterol"},{"key":"1503_CR30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.12300","volume":"37","author":"LH Nguyen","year":"2013","unstructured":"Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37:921\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"1503_CR31","doi-asserted-by":"publisher","unstructured":"Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, et al. Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per sustained virologic response. Hepatology. 2014; doi\/ 10.1002\/hep.v60.4\/issuetoc .","DOI":"10.1002\/hep.v60.4\/issuetoc"},{"key":"1503_CR32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.12788\/j.suponc.0011","volume":"11","author":"TL Truant","year":"2013","unstructured":"Truant TL, Porcino AJ, Ross BC, Wong ME, Hilario CT. Complementary and alternative medicine (CAM) use in advanced cancer: a systematic review. J Support Oncol. 2013;11:105\u201313.","journal-title":"J Support Oncol"},{"key":"1503_CR33","doi-asserted-by":"publisher","unstructured":"Abdullah MNA, Mohamed KMK, Ahmed TE, Abdullah AAM, Sulaiman AE, Omar AAY, et al. The use of and out-of-pocket spending on complementary and alternative medicine in Qassim province, Saudi Arabia. Ann Saudi Med 2013; doi: 10.5144\/0256-4947.2013.28","DOI":"10.5144\/0256-4947.2013.28"},{"key":"1503_CR34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","volume":"11","author":"MS Sulkowski","year":"2004","unstructured":"Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004;11:243\u201350.","journal-title":"J Viral Hepat"},{"key":"1503_CR35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pec.2005.06.019","volume":"62","author":"L Fraenkel","year":"2006","unstructured":"Fraenkel L, McGrawc S, Wongcharatrawee S, Garcia-Tsao G. Patients\u2019 experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns. 2006;62:148\u201355.","journal-title":"Patient Educ Couns"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-016-1503-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:10:59Z","timestamp":1498327859000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-016-1503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1186\/s12913-016-1503-6","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]},"article-number":"247"}}